Clinical Trial

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Study acronym: InDuRanS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-31; most recent amendment 2026-01-25.
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06810609
Lead Sponsor University Hospital, Bonn
Conditions Lung Cancer Non-Small Cell Cancer (NSCLC)
Enrollment 176 participants
Start Date 2025-04-20
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-27